このエントリーをはてなブックマークに追加
ID 53024
JaLCDOI
フルテキストURL
著者
Yamamoto, Tsuyoshi Iwakuni Clinical Center, National Hospital Organization
Kajikawa, Yutaka Fukuyama Medical Center,National Hospital Organization
Otani, Satoru Iwakuni Clinical Center, National Hospital Organization
Yamada, Yuki Iwakuni Clinical Center, National Hospital Organization
Takemoto, Syunji Fukuyama Medical Center,National Hospital Organization
Hirota, Minoru Fukuyama Medical Center,National Hospital Organization
Ikeda, Masae Fukuyama Medical Center,National Hospital Organization
Iwagaki, Hiromi Fukuyama Medical Center,National Hospital Organization
Saito, Shinya Graduate School of Health Sciences, Okayama University
Fujiwara, Toshiyoshi Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID 科研費研究者番号
抄録
Accumulated studies have shown that ω-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) have protective roles against inflammatory responses such as hyperlipidemia, diabetes mellitus (DM) and cardiovascular diseases. Here we examined the effects of administering EPA to hyperlipidemic patients and other patients undergoing cardiac surgery to determine whether this treatment would increase plasma EPA levels and to clarify the association between EPA treatment and adiponectin production in hyperlipidemic patients. We also assessed the effect of preoperative EPA administration on postoperative adverse events such as postoperative atrial fibrillation (POAF) and postoperative infection in the cardiac surgery patients. The EPA administration significantly increased the serum EPA concentrations in both patient populations (p<0.001). In the hyperlipidemic patients, the EPA administration significantly increased plasma adiponectin levels (p<0.05), accompanied by a decrease in insulin resistance designated by the HOMA-IR (homeostasis model assessment of insulin resistance) score (p<0.05) and Hs-CRP (high sensitivity C-reactive protein) value (p<0.05). In the cardiac surgery patients, no significant effect of EPA on cardiac adverse events such as POAF was observed. However, our results clearly demonstrated that both the neutrophil-to-lymphocyte ratio and the 2nd-line antibiotic requirement in the EPA group were significantly decreased compared to the untreated control group (p<0.05). We suggest that EPA administration may exert anti-inflammatory effects in patients with hyperlipidemia and in those undergoing cardiac surgery, possibly through an increase in plasma adiponectin levels.
キーワード
eicosapentaenoic acid
adiponectin
hyperlipidemic patients
cardiac surgery
atrial fibrillation
Amo Type
Original Article
発行日
2014-12
出版物タイトル
Acta Medica Okayama
68巻
6号
出版者
Okayama University Medical School
開始ページ
349
終了ページ
361
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT
関連URL
http://ousar.lib.okayama-u.ac.jp/metadata/53125